Back to results
US 2026/0265388 A1Published application
Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjögren's syndrome
AssigneeViela Bio, Inc.
InventorsIlias ALEVIZOS, Gabor G. ILLEI, William A. REES, Jorn DRAPPA, Liangwei WANG
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods comprising a CD40L-specific Tn3 scaffold. Also provided are methods of utilizing the same for the prevention and treatment of Sjögren's Syndrome.
Claims20
1-35. (canceled)
A method for treating Sjögren's syndrome (SS) in a subject in need thereof comprising:
- administering a Tn3 scaffold comprising two CD40L-specific monomer subunits and a human serum albumin to the subject;
- wherein the monomer subunits comprise seven beta strands designated A, B, C, D, E, F, and G, and six loop regions designated AB, BC, CD, DE, EF, and FG,
- wherein the AB loop comprises SEQ ID NO:
- 11, the BC loop comprises SEQ ID NO:
- 12, the CD loop comprises SEQ ID NO:
- 13, the DE loop comprises SEQ ID NO:
- 14, the EF loop comprises SEQ ID NO:
- 15, and the FG loop SEQ ID NO:
- 16,
- and wherein the Tn3 scaffold is administered at a dose of about 3000 mg every 12 weeks.
7 more elements
A method for treating Sjögren's syndrome (SS) in a subject in need thereof comprising:
- administering a Tn3 scaffold comprising SEQ ID NO:
- 1, and wherein the Tn3 scaffold is administered at a dose of about 3000 mg every 12 weeks.
A method for treating Sjögren's syndrome (SS) in a subject in need thereof comprising:
- administering a Tn3 scaffold comprising SEQ ID NO:
- 1, wherein the Tn3 scaffold is administered at a dose of about 3000 mg every 12 weeks, and wherein the subject receives a loading dose of 3000 mg of the Tn3 scaffold about four weeks after the first dose.
Dependencies are inferred from the claim text.